THSD7A Positivity Is Associated with High Expression of FAK in Prostate Cancer

Prostate cancer is one of the most common malignancies, and there are a wide range of treatment options after diagnosis. Most prostate cancers behave in an indolent manner. However, a given sub-group has been shown to exhibit aggressive behavior; therefore, it is desirable to find novel prognostic a...

Full description

Bibliographic Details
Main Authors: Fidelis Andrea Flockerzi, Johannes Hohneck, Matthias Saar, Rainer Maria Bohle, Phillip Rolf Stahl
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/13/2/221
_version_ 1797443826518851584
author Fidelis Andrea Flockerzi
Johannes Hohneck
Matthias Saar
Rainer Maria Bohle
Phillip Rolf Stahl
author_facet Fidelis Andrea Flockerzi
Johannes Hohneck
Matthias Saar
Rainer Maria Bohle
Phillip Rolf Stahl
author_sort Fidelis Andrea Flockerzi
collection DOAJ
description Prostate cancer is one of the most common malignancies, and there are a wide range of treatment options after diagnosis. Most prostate cancers behave in an indolent manner. However, a given sub-group has been shown to exhibit aggressive behavior; therefore, it is desirable to find novel prognostic and predictive (molecular) markers. THSD7A expression is significantly associated with unfavorable prognostic parameters in prostate cancer. FAK is overexpressed in several tumor types and is believed to play a role in tumor progression and metastasis. Furthermore, there is evidence that THSD7A might affect FAK-dependent signaling pathways. To examine whether THSD7A expression has an impact on the expression level of FAK in its unphosphorylated form, a total of 461 prostate cancers were analyzed by immunohistochemistry using tissue microarrays. THSD7A positivity and low FAK expression were associated with adverse pathological features. THSD7A positivity was significantly associated with high FAK expression. To our knowledge we are the first to show that THSD7A positivity is associated with high FAK expression in prostate cancer. This might be proof of the actual involvement of THSD7A in FAK-dependent signaling pathways. This is of special importance because THSD7A might also serve as a putative therapeutic target in cancer therapy.
first_indexed 2024-03-09T13:03:39Z
format Article
id doaj.art-4e0898bf36864a76a63f11fcca4b6ece
institution Directory Open Access Journal
issn 2075-4418
language English
last_indexed 2024-03-09T13:03:39Z
publishDate 2023-01-01
publisher MDPI AG
record_format Article
series Diagnostics
spelling doaj.art-4e0898bf36864a76a63f11fcca4b6ece2023-11-30T21:51:41ZengMDPI AGDiagnostics2075-44182023-01-0113222110.3390/diagnostics13020221THSD7A Positivity Is Associated with High Expression of FAK in Prostate CancerFidelis Andrea Flockerzi0Johannes Hohneck1Matthias Saar2Rainer Maria Bohle3Phillip Rolf Stahl4Department of Pathology, Saarland University Medical Center, 66421 Homburg, GermanyDepartment of Pathology, Saarland University Medical Center, 66421 Homburg, GermanyDepartment of Urology, University Hospital, 52074 Aachen, GermanyDepartment of Pathology, Saarland University Medical Center, 66421 Homburg, GermanyDepartment of Pathology, Saarland University Medical Center, 66421 Homburg, GermanyProstate cancer is one of the most common malignancies, and there are a wide range of treatment options after diagnosis. Most prostate cancers behave in an indolent manner. However, a given sub-group has been shown to exhibit aggressive behavior; therefore, it is desirable to find novel prognostic and predictive (molecular) markers. THSD7A expression is significantly associated with unfavorable prognostic parameters in prostate cancer. FAK is overexpressed in several tumor types and is believed to play a role in tumor progression and metastasis. Furthermore, there is evidence that THSD7A might affect FAK-dependent signaling pathways. To examine whether THSD7A expression has an impact on the expression level of FAK in its unphosphorylated form, a total of 461 prostate cancers were analyzed by immunohistochemistry using tissue microarrays. THSD7A positivity and low FAK expression were associated with adverse pathological features. THSD7A positivity was significantly associated with high FAK expression. To our knowledge we are the first to show that THSD7A positivity is associated with high FAK expression in prostate cancer. This might be proof of the actual involvement of THSD7A in FAK-dependent signaling pathways. This is of special importance because THSD7A might also serve as a putative therapeutic target in cancer therapy.https://www.mdpi.com/2075-4418/13/2/221THSD7AFAKprostate cancer
spellingShingle Fidelis Andrea Flockerzi
Johannes Hohneck
Matthias Saar
Rainer Maria Bohle
Phillip Rolf Stahl
THSD7A Positivity Is Associated with High Expression of FAK in Prostate Cancer
Diagnostics
THSD7A
FAK
prostate cancer
title THSD7A Positivity Is Associated with High Expression of FAK in Prostate Cancer
title_full THSD7A Positivity Is Associated with High Expression of FAK in Prostate Cancer
title_fullStr THSD7A Positivity Is Associated with High Expression of FAK in Prostate Cancer
title_full_unstemmed THSD7A Positivity Is Associated with High Expression of FAK in Prostate Cancer
title_short THSD7A Positivity Is Associated with High Expression of FAK in Prostate Cancer
title_sort thsd7a positivity is associated with high expression of fak in prostate cancer
topic THSD7A
FAK
prostate cancer
url https://www.mdpi.com/2075-4418/13/2/221
work_keys_str_mv AT fidelisandreaflockerzi thsd7apositivityisassociatedwithhighexpressionoffakinprostatecancer
AT johanneshohneck thsd7apositivityisassociatedwithhighexpressionoffakinprostatecancer
AT matthiassaar thsd7apositivityisassociatedwithhighexpressionoffakinprostatecancer
AT rainermariabohle thsd7apositivityisassociatedwithhighexpressionoffakinprostatecancer
AT philliprolfstahl thsd7apositivityisassociatedwithhighexpressionoffakinprostatecancer